Evidence map›Paper›PMID 29974132›Full record

ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2018

Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment.

David Krug, René Baumann, Wilfried Budach, Jürgen Dunst, Petra Feyer, Rainer Fietkau, Wulf Haase, Wolfgang Harms, Thomas Hehr, Marc D Piroth and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Quality of life and fatigue before and after radiotherapy in breast cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  10. Review
  11. Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Article
  12. Post-Neoadjuvant Therapy.Breast care (Basel, Switzerland) · 2019
    Article
  13. Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019
    Article
  14. Review
  15. Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

David KrugDepartment of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. davidkrug@gmx.de.ORCID http://orcid.org/0000-0001-8811-5416
René BaumannUniversity Hospital Schleswig-Holstein, Kiel, Germany.
Wilfried BudachDepartment of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Jürgen DunstUniversity Hospital Schleswig-Holstein, Kiel, Germany.
Petra FeyerVivantes Hospital Neukölln, Berlin, Germany.
Rainer FietkauUniversity Hospital Erlangen, Erlangen, Germany.
Wulf HaaseFormerly St.-Vincentius-Hospital, Karlsruhe, Germany.
Wolfgang HarmsSt. Claraspital, Basel, Switzerland.
Thomas HehrDepartment of Radiation Oncology, Marienhospital Stuttgart, Stuttgart, Germany.
Marc D PirothHELIOS-Hospital Wuppertal, Witten/Herdecke University, Wuppertal, Germany.
Felix SedlmayerParacelsus Medical University Hospital, Salzburg, Austria.
Rainer SouchonFormerly University Hospital Tuebingen, Tuebingen, Germany.
Frederik WenzUniversity Hospital Mannheim, Mannheim, Germany.
Rolf SauerUniversity Hospital Erlangen, Erlangen, Germany.
Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant chemotherapy (NACT) has been widely adopted into the multidisciplinary management of breast cancer. The prognostic impact of treatment response has been clearly demonstrated. However, the impact of treatment response on the indication for adjuvant radiotherapy is unclear. This review summarizes important implications of NACT and treatment response on the risk of recurrence and locoregional multidisciplinary management from the standpoint of radiation oncology.

Indexed as

MastectomyRadiotherapy, AdjuvantBreast NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalFollow-Up StudiesHumansInterdisciplinary CommunicationIntersectoral CollaborationNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm, ResidualNeoplasm StagingPrognosisSentinel Lymph Node BiopsyNeoadjuvant treatmentNeoplasm recurrence, localPost-mastectomy radiotherapyRegional nodal irradiationSentinel lymph node biopsy

Identifiers

PMID29974132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.